Attenuation of radiation- and chemoradiation-induced mucositis using gamma-d-glutamyl-l-tryptophan (SCV-07)

Authors


Dr Stephen Sonis, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. Tel: 617 525 6864, Fax: 617 582 6022, E-mail: ssonis@partners.org

Abstract

Oral Diseases (2010) 16, 655–660

Objective:  To evaluate the efficacy of a novel immunomodulating peptide (SCV-07) in attenuating the course of radiation-induced mucositis in an established animal model of oral mucositis (OM).

Material and Methods:  In three separate experiments, golden Syrian hamsters received either an acute radiation challenge to the buccal mucosa of eight fractionated doses of 7.5 Gy of radiation over a 2-week-period, or a combination of acute radiation and cisplatin. In each experiment, animals were treated with varying doses or schedules of SCV-07 or placebo. OM was scored in a blinded fashion using digital images obtained during the experimental period.

Results:  We found that SCV-07 reduced the severity and duration of both acute and fractionated radiation-induced OM. Similarly, when radiation and chemotherapy were used to induce OM, treatment with SCV-07 significantly reduced the duration of ulcerative OM. The therapeutic benefit was dependent on both dose and schedule of administration.

Conclusion:  Taken together, we found SCV-07 was able to modify the duration and severity of oral mucositis and was dependent on schedule and dose.

Ancillary